Leukemia, Lymphocytic, Chronic, B-Cell × Sorafenib × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
NCT00474929 2019-08-20

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
103 enrolled 12 charts
NCT00118170 2013-01-07

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

National Cancer Institute (NCI)

Phase 1 Completed
150 enrolled